Illustration of diverse patient subgroups receiving tailored healthcare.

Decoding High-Cost Healthcare: Unveiling Subgroups for Better Care

Beau Callahan in Health & Wellness December 2025 • 5 min read.

"A deep dive into the factors driving healthcare costs and how tailored strategies can improve outcomes."

The rising costs of healthcare have become a pressing concern for individuals, policymakers, and healthcare providers alike. Understanding the dynamics behind these costs is crucial for developing effective strategies to improve patient care and optimize resource allocation. Within the Medicare Advantage (MA) system, a significant portion of healthcare spending is concentrated among a small group of high-cost patients.

Recent research sheds light on the composition of these high-cost populations, revealing that they are not a homogenous group. Instead, they comprise various subgroups with distinct clinical profiles, utilization patterns, and healthcare needs. Recognizing these differences is essential for creating tailored care management programs that address the unique challenges faced by each group.

This article aims to decode the complexities of high-cost healthcare by exploring the characteristics of these subgroups. By examining their demographics, clinical conditions, and healthcare utilization patterns, we can gain valuable insights into the factors driving costs and identify opportunities for targeted interventions that lead to improved patient outcomes and more efficient use of healthcare resources.

Unveiling the High-Cost Landscape: Key Subgroups and Their Distinct Needs

Illustration of diverse patient subgroups receiving tailored healthcare.

A recent observational study delved into the Medicare Advantage population to identify and analyze the key subgroups within the high-cost patient cohort. The study utilized a density-based clustering algorithm to group patients based on 161 distinct demographic, clinical, and claims-based variables. This method allowed researchers to identify ten distinct subgroups, each with unique characteristics and healthcare needs.

These subgroups offer a more granular understanding of the high-cost landscape, highlighting the diversity of patient experiences and the complexity of their healthcare journeys. Understanding these patterns can guide the development of targeted interventions and care management strategies.

Acute Exacerbations of Chronic Disease (Mixed): This group is characterized by procedures related to acute hospitalizations and a higher incidence of conditions like cerebrovascular disease and heart failure. They also show higher rates of preventable spending.
End-Stage Renal Disease (ESRD): This group, with the highest average spending, exhibits conditions and procedures linked to ESRD and dialysis. They also have the highest rates of persistent high-cost status.
Recurrent Gastrointestinal Bleed (GIB): Patients in this subgroup are defined by conditions and procedures related to GIB, with high rates of ED and inpatient utilization.
Orthopedic Trauma (Trauma): Characterized by procedures related to fractures and other traumatic events, this subgroup presents with the highest inpatient utilization rates.
Vascular Disease (Vascular): With lower rates of utilization and spending, this group is associated with peripheral vascular disease.
Surgical Infections and Other Complications (Complications): This group experiences higher inpatient utilization and total spending due to surgical complications.
Cirrhosis with Hepatitis C (Liver): Patients in this subgroup have the highest average spending, primarily driven by prescription drug costs.
ESRD with Increased Medical and Behavioral Comorbidity (ESRD+): This subgroup is marked by higher rates of various comorbidities, with high preventable spending and persistent high-cost status.
Cancer with High-Cost Imaging and Radiation Therapy (Oncology): Driven by cancer diagnoses and related procedures, this group has relatively low mortality rates.
Neurologic Disorders (Neurologic): This group, with spending largely driven by prescription drugs, has among the lowest inpatient utilization rates.

The study revealed that each subgroup exhibits unique utilization, spending, and mortality patterns. For instance, the ESRD subgroup showed significantly higher spending and mortality rates compared to the trauma group, which had the highest inpatient utilization. The cancer subgroup, on the other hand, presented with lower mortality rates than the ESRD+ group. This variability underscores the importance of tailored interventions that address the specific needs of each subgroup. These findings hold critical implications for the design and implementation of care management programs, as uniform strategies are unlikely to be effective across all groups.

Moving Forward: Tailoring Solutions for a Complex Landscape

The identification of distinct subgroups within high-cost healthcare populations offers a promising pathway toward more effective care management and resource allocation. By understanding the unique characteristics and needs of each group, healthcare providers and policymakers can develop targeted interventions that improve patient outcomes while optimizing healthcare spending. Moving forward, a focus on personalized care strategies, robust data analysis, and ongoing evaluation will be crucial in navigating the complexities of high-cost healthcare and building a more sustainable and patient-centered system.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

What are the primary factors contributing to high healthcare costs within the Medicare Advantage system?

High healthcare costs in the Medicare Advantage system are largely driven by a small percentage of patients with complex needs. These high-cost patients are not a homogenous group, but rather consist of distinct subgroups with varying clinical profiles, healthcare utilization patterns, and specific healthcare requirements. Identifying and understanding these subgroups is essential for developing effective strategies to manage costs and improve patient care. Factors include, Acute Exacerbations of Chronic Disease, End-Stage Renal Disease, Recurrent Gastrointestinal Bleed, Orthopedic Trauma, Vascular Disease, Surgical Infections and Other Complications, Cirrhosis with Hepatitis C, ESRD with Increased Medical and Behavioral Comorbidity, Cancer with High-Cost Imaging and Radiation Therapy and Neurologic Disorders.

How did the observational study identify the different subgroups within the high-cost Medicare Advantage population?

The observational study used a density-based clustering algorithm to group patients based on 161 distinct demographic, clinical, and claims-based variables. This method enabled the researchers to identify ten distinct subgroups within the high-cost Medicare Advantage population. These subgroups include: Acute Exacerbations of Chronic Disease, End-Stage Renal Disease (ESRD), Recurrent Gastrointestinal Bleed, Orthopedic Trauma, Vascular Disease, Surgical Infections and Other Complications, Cirrhosis with Hepatitis C, ESRD with Increased Medical and Behavioral Comorbidity, Cancer with High-Cost Imaging and Radiation Therapy, and Neurologic Disorders. Each subgroup is characterized by unique healthcare needs and utilization patterns.

What are some examples of the distinct characteristics observed among the different high-cost subgroups in the Medicare Advantage population?

Each subgroup exhibits unique utilization, spending, and mortality patterns. For instance, the End-Stage Renal Disease subgroup shows significantly higher spending and mortality rates compared to the Orthopedic Trauma group, which has the highest inpatient utilization. In contrast, the Cancer subgroup presents with lower mortality rates compared to the ESRD with Increased Medical and Behavioral Comorbidity group. These variations highlight the necessity for tailored interventions that address the specific needs of each subgroup. The Acute Exacerbations of Chronic Disease subgroup shows higher rates of preventable spending.

What are the implications of identifying these distinct subgroups for the design and implementation of care management programs?

Identifying distinct subgroups emphasizes that uniform care management strategies are unlikely to be effective across all high-cost patients. Instead, healthcare providers and policymakers can develop targeted interventions that improve patient outcomes while optimizing healthcare spending. These interventions should be tailored to the specific characteristics and needs of each subgroup, considering their demographics, clinical conditions, and healthcare utilization patterns. Personalized care strategies, robust data analysis, and ongoing evaluation are crucial for navigating the complexities of high-cost healthcare.

In what ways does the Cirrhosis with Hepatitis C subgroup differ from other high-cost subgroups, and what implications does this have for treatment strategies?

The Cirrhosis with Hepatitis C subgroup stands out because its high average spending is primarily driven by prescription drug costs, whereas other subgroups may have costs driven more by inpatient utilization or procedures. This difference implies that treatment strategies for this group should focus on optimizing medication management, ensuring adherence, and potentially exploring cost-effective alternatives when appropriate. It also highlights the importance of addressing hepatitis C, as effective treatment can reduce liver damage and potentially lower the overall healthcare costs associated with this subgroup. The ESRD subgroup, in contrast, is defined by conditions and procedures linked to ESRD and dialysis and exhibit the highest rates of persistent high-cost status.